Leucomethylene blue mesylate (TRx0237 mesylate) is a second-generation tau protein aggregation inhibitor for the treatment of Alzheimer’s disease (AD) and frontotemporal dementia.
More Information Supplier Page
Leucomethylene blue mesylate (TRx0237 mesylate) is a second-generation tau protein aggregation inhibitor for the treatment of Alzheimer’s disease (AD) and frontotemporal dementia.
More Information Supplier Page 
Upadacitinib (ABT-494) is a selective Janus kinase (JAK) 1 inhibitor, which is being studied for the treatment of several autoimmune disorders in the IC50 of 43 nM.
More Information Supplier Page
Upadacitinib (ABT-494) is a selective Janus kinase (JAK) 1 inhibitor, which is being studied for the treatment of several autoimmune disorders in the IC50 of 43 nM.
More Information Supplier Page Upadacitinib (ABT-494) is a selective Janus kinase (JAK) 1 inhibitor, which is being studied for the treatment of several autoimmune disorders in the IC50 of 43 nM.
More Information Supplier Page Upadacitinib (ABT-494) is a selective Janus kinase (JAK) 1 inhibitor, which is being studied for the treatment of several autoimmune disorders in the IC50 of 43 nM.
More Information Supplier Page 
2,4′-Dihydroxybenzophenone can effectively protect C57BL/6J mice from APAP-induced hepatotoxicity. Its mechanisms might be associated with its Antioxidant activity.
More Information Supplier Page
Leucomethylene blue mesylate (TRx0237 mesylate) is a second-generation tau protein aggregation inhibitor for the treatment of Alzheimer’s disease (AD) and frontotemporal dementia.
More Information Supplier Page
Leucomethylene blue mesylate (TRx0237 mesylate) is a second-generation tau protein aggregation inhibitor for the treatment of Alzheimer’s disease (AD) and frontotemporal dementia.
More Information Supplier Page 
Lercanidipine hydrochloride is a calcium channel blocker of the dihydropyridine class.
More Information Supplier Page
